Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 728 across all filing types
Latest filing 2022-07-04 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, registered in the Cayman Islands and listed on the Hong Kong Stock Exchange. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A) which require disclosure of share capital changes. The document details share issuance under share award plans and stock options, including dates, share counts, and prices. It also includes formal confirmations by the company's CFO regarding authorization and compliance with listing rules. The document length is about 3,072 characters, which is relatively short but contains detailed data on share issuance and capital changes, not merely an announcement of a report or a certification. This fits the definition of a Share Issue/Capital Change announcement rather than a full financial report or a regulatory filing. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2022-07-04 Chinese
百济神州有限公司自愿披露关于在2022年欧洲肿瘤内科学会世界胃肠癌大会上展示百泽安（替雷利珠单抗注射液）最新数据的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by BeiGene Ltd. about the latest clinical trial data (RATIONALE 306) presented at the 2022 European Society for Medical Oncology (ESMO) World Gastrointestinal Cancer Congress. It details clinical trial results for a drug (Tislelizumab injection) and includes risk warnings related to drug development and regulatory approval uncertainties. The document is an announcement of clinical data and related information, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or management discussion. It is also not a report publication announcement since it does not mention an attached report or provide a link to a report. The content is primarily a regulatory announcement about clinical trial results and associated risks, fitting best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2022-06-30 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 100% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, registered in the Cayman Islands and listed on the Hong Kong Stock Exchange. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A) which require disclosure of share capital changes. The document includes detailed tables of share issuance and repurchase data, dates, share counts, prices, and compliance statements. It is not an announcement of a report publication but the actual disclosure itself. The content is regulatory and compliance-related but specifically about share capital changes, not a general regulatory filing or a report publication announcement. Therefore, the most appropriate classification is "Share Issue/Capital Change (SHA)". The document length is under 5,000 characters but contains substantive data on share capital changes, so it is not just an announcement but the actual disclosure report.
2022-06-30 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, registered in the Cayman Islands and listed on the Hong Kong Stock Exchange. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A) which require disclosure of share capital changes. The document includes detailed tables of share issuance and share counts, dates, prices, and percentage changes. It also contains formal confirmations by company officers regarding the authorization and compliance of the share issuance. The document length is 2886 characters, which is relatively short but contains substantive data on share capital changes, not merely an announcement of a report or a certification. This fits the category of Share Issue/Capital Change announcements, as it reports on new share issuance and changes in share capital structure. It is not an Annual Report, Earnings Release, or Regulatory Filing, nor is it a report publication announcement. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2022-06-29 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, registered in the Cayman Islands and listed on the Hong Kong Stock Exchange. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A) which require disclosure of changes in issued share capital. The document details share issuance under a share award plan, including dates, share quantities, and prices. It also includes formal confirmations by company officers regarding authorization and compliance with listing rules. The document length is about 3,027 characters, which is relatively short but contains detailed data on share issuance and capital changes, not merely an announcement of a report or a certification. This fits the definition of a Share Issue/Capital Change announcement rather than a full financial report or regulatory filing. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2022-06-27 Chinese
港股公告：授出购股权及向董事授出受限制股份单位
Director's Dealing Classification · 95% confidence The document is a detailed announcement regarding the granting of share options and restricted stock units to directors and employees under the 2016 Option and Incentive Plan. It includes specifics such as the number of options granted, exercise prices, vesting schedules, and the identities of recipients, including directors and senior executives. The content focuses on equity compensation awards rather than financial results, governance rules, or meeting materials. It is not a full financial report, earnings release, or management discussion. It is also not a proxy solicitation or voting results announcement. The document aligns with disclosures about director and executive share transactions or equity awards. Therefore, the most appropriate classification is Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives, including grants of stock options and restricted stock units.
2022-06-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.